NasdaqGM - Nasdaq Real Time Price USD

NewAmsterdam Pharma Company N.V. (NAMS)

18.37

-0.90

(-4.67%)

At close: May 9 at 4:00:00 PM EDT

18.00

-0.37

(-2.01%)

After hours: May 9 at 4:15:45 PM EDT

NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024)

NewAmsterdam Pharma ( NASDAQ:NAMS ) First Quarter 2025 Results Key Financial Results Revenue: US$2.98m (up 113% from 1Q...

Simply Wall St. 2 hours ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- Company to host R&D day on June 11th, 2025 in New York City -- –$808.5 million in cash, cash equivalents and marketable securities at March 31, 2025 – NAARDEN, The Netherlands and MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N

GlobeNewswire 2 days ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination with ezetimibe or as monotherapy, reduced LDL-C by 50% and 35%, respectively; in addition, Phase 2 data of obicetrapib in combination with moderate-dose statins showed LDL-C reductions of approximately 70% – – 21% observed reduction in major ad

GlobeNewswire 3 days ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s

GlobeNewswire 7 days ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkersNAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholestero

GlobeNewswire 10 days ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent

GlobeNewswire 22 days ago

NAMS
-4.67%

NAMSW
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.

Investor's Business Daily last month

NAMS
-4.67%

NAMSW

AZN
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of New

GlobeNewswire last month

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year

Shareholders of NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) will be pleased this week, given that the stock price...

Simply Wall St. 2 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

NewAmsterdam Pharma ( NASDAQ:NAMS ) Full Year 2024 Results Key Financial Results Revenue: US$45.6m (up 223% from FY...

Simply Wall St. 2 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- -- Phase 3 PREVAIL CVOT remains on track -- -- $834.2 million in cash, cash equivalents and marketable securities at December 31, 2024 -- NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing

GlobeNewswire 2 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the f

GlobeNewswire 2 months ago

NAMS
-4.67%

NAMSW
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease

Key Insights NewAmsterdam Pharma's significant private equity firms ownership suggests that the key decisions are...

Simply Wall St. 2 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewA

GlobeNewswire 3 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini – -- Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib alone and in combination with a PCSK9i on Lp(a) – -- Focus on commercial readiness with manufacturing capacity establishment and inventory build-out -- -- Year end, unaudited, cash balance of $835 mil

GlobeNewswire 3 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritte

GlobeNewswire 4 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritte

GlobeNewswire 4 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investor's Business Daily 4 months ago

ADMA

CORT

CPRX
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted.

Investor's Business Daily 4 months ago

NAMS
-4.67%

NAMSW
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering

GlobeNewswire 4 months ago

NAMS
-4.67%

NAMSW

Performance Overview

Return	NAMS	S&P 500 (^GSPC)
YTD	-28.52%	-3.77%
1-Year	-15.97%	+8.55%
3-Year	+86.50%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year

NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Performance Overview